{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-246775","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2025-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.907776+00:00","generated_at":"2026-05-17T02:46:01.390741+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Viking Therapeutics Reports Q3 2025 Results, Cash $715M, VK2735 Phase 3 Trials On Track","bullets":["Q3 2025 net loss $90.8M ($0.81/share) vs $24.9M in Q3 2024; R&D expenses rose to $90.0M from $22.8M.","Cash, equivalents and short-term investments totaled $715M as of Sept 30, 2025, down from $903M at Dec 31, 2024.","Phase 3 VANQUISH-1 for VK2735 in obesity expects enrollment completion by end of 2025; VANQUISH-2 by Q1 2026.","Phase 2 VENTURE-Oral study showed up to 12.2% mean weight loss after 13 weeks; up to 97% achieved ≥5% weight loss.","Maintenance dosing study of VK2735 initiated; plans to file IND for dual amylin/calcitonin agonist in Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-246775","json":"https://secwatch.observer/filing/0001193125-25-246775.json","markdown":"https://secwatch.observer/filing/0001193125-25-246775.md","text":"https://secwatch.observer/filing/0001193125-25-246775.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000119312525246775/0001193125-25-246775-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000119312525246775/vktx-20251022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T02:46:01.390741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}